Opportunity timeline

PostedSep 8, 2026
DeadlineDec 9, 2026

In plain English

Los Alamos National Laboratory is offering TIDAL, a protein-only technology that uses nanobodies to form target-triggered droplets. Potential applications include resin-free protein purification, slow-release drug delivery, intracellular protein trapping, and more sensitive diagnostics. The technology is at TRL 3, has a U.S. patent pending, and is available to companies through exclusive or non-exclusive licensing agreements; this is not a request for outside development services.

About this opportunity

Developed by Los Alamos National Laboratory, TIDAL (Target-Induced Droplet Assembly of Ligands) transforms the small antibody fragments known as nanobodies into a programmable, protein-only material that organizes itself on demand. By harnessing a natural process called liquid-liquid phase separation, TIDAL lets these binders gather into dense, dynamic droplets precisely when they encounter their intended target, giving developers a single platform that can purify proteins without costly resins, deliver drugs as a self-forming slow-release depot and even trap harmful proteins inside living cells. The outcome is a versatile toolkit that lowers production costs, simplifies manufacturing and…

Time remaining

Closes Dec 9, 2026

85Days
:
19Hours
:
48Min
:
53Sec

Related Opportunities

Bid details are gathered and summarized automatically. Please verify details at the original source.

Ref No.

BS-CD5E58